RxDoctor Payments Data

Richard Shaw, MD

Family Medicine · Simi Valley, CANPI 1376537753

Payments from drug & device makers

$12,565in general payments, 2019–2025

Across 527 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$489
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$12,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,565 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$143,337
Medicare patients
383
Services billed
1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$76,812
RybelsusSemaglutide33$62,931
EliquisApixaban42$46,323
XareltoRivaroxaban25$37,872
OzempicSemaglutide34$33,750
JanuviaSitagliptin Phosphate23$33,262
ProliaDenosumab16$26,951
Breo ElliptaFluticasone/Vilanterol30$14,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,323
Spiriva RespimatTiotropium Bromide12$7,839
Repatha SureclickEvolocumab11$5,883
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$5,728
Atorvastatin Calcium566$5,225
BreynaBudesonide/Formoterol Fumarate20$4,478
Duloxetine Hcl145$4,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,787$96,68167 claims
Boehringer IngelheimJardiance, Spiriva Respimat$1,242$84,65281 claims
PfizerEliquis$120$46,32342 claims
Johnson & JohnsonXarelto$426$37,87225 claims
MerckJanuvia$266$33,26223 claims
GSKBreo Ellipta, Trelegy Ellipta$332$27,53048 claims
AmgenProlia$1,317$26,95116 claims
AbbVieSynthroid$2,130$2,00027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Simi Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →